Replies to post #349523 on Anavex Life Sciences Corp (AVXL)

[pcguy]

Add to this a shaky market.

[Investor2014]

The concerns you outline are true, however much of these complaints may ultimately be explained by a less traditional approach to the clinical trials design and execution process.

Over a number of years, for me since early 2015, Anavex have run only small trials with good spacing between them. Not the P1, one or more P2s and finally one or more P3 trials in one indication hoping something sticks all while wearing an Aduhelm for protection.

Instead it seems Missling favours low budget few smaller trials, while using the spacing between them for learning, pontificating and designing by researching the full The Ontology of Clinical Research (OCRe): An Informatics Foundation for the Science of Clinical Research as discussed in the paper.

Armed with all possible knowledge then initiate and run a clinical trials programme taking the time it takes, all the while combined with the latest tools and techniques e.g Ariana KEM Analysis, full genome sequencing, gut microbiome sequencing etc. Then along the way stuffing ever more data with more parameters into the sausage machine and ponder the output.

This approach if done right should be smarter than a shotgun approach when the situation in fact calls for a sniper.

Lol, hopefully that analogy works well for my friends in the land of much freedom and fraud.

We may have this!

Sunday greetings from a Covid restriction and mandated vaccine free Candyland.

Inv2014

[WolfofMia]

Well sounds like you are displeased and probably dont hold an AVXL position anymore since you consider it too risky.

Specially in a shaky market.

Thanks for the warning, farewell take care.

[512]

You could have just said:

“This is an unproven baby-bio we’re invested in!”

Lol

[La Flaca]

Your “duck” is my gem.